Crossject【ALCJ】銘柄情報 | ADVFN

US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
ヨーロッパ
EU
Crossject (ALCJ) 銘柄情報

Crossject (ALCJ)

2.095

-0.065

(-3.01%)

終了 11月13日 1:30AM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

2.095

買値

2.07

売値

2.13

出来高

39,532

2.06 日の範囲 2.15

1.52 52 週間の範囲 5.96

時価総額

前日終値

2.16

始値

2.15

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

76,158

発行済株式数

36,763,256

配当利回り

-

PER

-8.89

1 株当たり利益 (EPS)

-0.24

歳入

9.14M

純利益

-8.64M

セクター

Med, Dental, Hosp Eq-whsl

業界

Med, Dental, Hosp Eq-whsl

ウェブサイト

www.crossject.com

本社

Dijon, Cote-d'or, Fra

設立

-

Crossject is listed in the Med, Dental, Hosp Eq-whsl sector of the ユーロネクスト with ticker ALCJ. The last closing price for Crossject was 2.16 €. Over the last year, Crossject shares have traded in a share price range of 1.52 € to 5.96 €.

Crossject currently has 36,763,256 shares in issue. The market capitalisation of Crossject is 79.41 € million. Crossject has a price to earnings ratio (PE ratio) of -8.89.

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to...

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization Product batch announced in July yielded new regulatory...

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et...

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et...

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et...

Crossject annonce son éligibilité au dispositif d’investissement PEA-PME

Crossject annonce son éligibilité au dispositif d’investissement PEA-PME Le PEA-PME permet aux investisseurs particuliers français d'acheter des titres à des conditions fiscales préférentielles...

Crossject announces its eligibility for France’s PEA-PME investment scheme

Crossject announces its eligibility for France’s PEA-PME investment scheme Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024...

Crossject présente ses résultats financiers et les faits marquants de ses activités pour le premier semestre 2024

Crossject présente ses résultats financiers et les faits marquants de ses activités pour le premier semestre 2024 Position de trésorerie : 5,95 millions d'euros, contre 2,3 millions d’euros au 31...

Crossject reports financial results and business highlights for the first six months of 2024

Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file...

Crossject reports financial results and business highlights for the first six months of 2024

Crossject reports financial results and business highlights for the first six months of 2024 Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.115	5.80808080808	1.98	2.235	1.85	92927	2.04646178	DE
4	-0.315	-13.0705394191	2.41	2.75	1.85	100631	2.27847286	DE
12	0.105	5.27638190955	1.99	2.75	1.85	76158	2.27972571	DE
26	-0.03	-1.41176470588	2.125	2.75	1.52	73933	2.07380788	DE
52	-2.255	-51.8390804598	4.35	5.96	1.52	86027	3.05393033	DE
156	-1.02	-32.7447833066	3.115	5.96	1.408	84720	3.29583238	DE
260	-0.675	-24.3682310469	2.77	5.96	1.04	131310	3.03162725	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MLGEQGentlemen S Equity SA	0.017 € (70.00%)	1,000
BE0945331669ARKimedes Fonds NV	5.80 € (49.48%)	50
ALAMAAMA Corporation PLC	0.192 € (28.00%)	41.28k
VACBSPierre & Vacances	0.062 € (16.98%)	21.54k
CNVCnova NV	0.534 € (16.09%)	10.38k
BALDSBalyo DS	0.015 € (-97.16%)	1.26M
MLWEYWeya	0.011 € (-78.00%)	49.4k
ALGAUGaussin	0.0618 € (-47.98%)	1.07M
MLAALagence Automobiliere SA	0.58 € (-45.79%)	315
ALVIAVialife Sa	11.10 € (-41.58%)	129
ALNEVNeovacs	0.0002 € (0.00%)	108.4M
BCPBanco Comercial Portugues SA	0.443 € (-2.32%)	51.43M
ALTDTonner Drones	0.0092 € (12.20%)	13.61M
ALSRSSirius Media	0.0158 € (-24.76%)	10.39M
ORAOrange.	9.754 € (-2.13%)	10.08M

dennisdave

dennisdave 1分前

A Direct program is useless unless MHRA approves L. And direct is useless without renewed medical trials which cost at least $150 million if not more. Therefore IMO NWBO is anticipating a cash injection (hopefully non dilutive from a big pharma) and is expecting approval soon.

glenn1919

glenn1919 1分前

muln.............................................A/H

Iron heart

Iron heart 2分前

Patience is the key! GLTA $CGAC

dinogreeves

dinogreeves 2分前

Now, this is all agreed on all fronts, which makes total sense.

getmoreshares

getmoreshares 2分前

actually hit .001

Invest-in-America

Invest-in-America 2分前

MULN: May I conclude then, Young Lady, that you simply do NOT like this firm from any conceivable perspective???

https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExaXBrNTc1NHBoZWR4bXB1c29wcGRsbTh2emF3cDB1d2p6OHA2eW53ZyZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9cw/a8uMrItvbj46A9bhud/giphy.gif

SSKILLZ1

SSKILLZ1 2分前

~~COMPX 11/13/2024~~~~~~~

Previous Close

19,281.40 -17.36

19199 SSKILLZ1

newmedman

newmedman 2分前

LOL I learned how to play golf while everyone else was trying out for the football team.. I found out that I didn't belong there either but they liked the drugs I got them and going to rock concerts all night.

ChannelTrader

ChannelTrader 2分前

flipper44

flipper44 3分前

It’s developed. It needs to be trialed.

PonderosaPack

PonderosaPack 3分前

I take Seeking alpha with a grain of salt. Just relaying new info (good or bad). Hopefully - this will be good. The points raised in the articles however are legit and make sense to me.

FeMike

I’d speculate the completed contracts are with Merck and Oncovir. Just a guess based on Keytruda and Poly-iclc trials with DCVax-l.

Yeh, no confidence at all but that's certainly the ring I'd throw my hat in if I had to.

rbl100

Diddy and Epstein lists are coming soon to a theater near you. Videos are included.

Wait till you all find out who is on them. I can tell you right now, they are all Kamala supporters. And yes there are RINO's included. Many will try to leave the country but will be taken into custody

attilathehunt

attilathehunt 4分前

Direct to start by end of January so perhaps not a lengthy delay.

glenn1919

glenn1919 4分前

MULN...........................................a/h
https://www.stockscores.com/charts/charts/?ticker=MULN

STILL TOWING

STILL TOWING 4分前

My guess is Ward has sent out multiple thumbs up in the last 12 hrs and things are good..Better than good...👍

dennisdave

dennisdave 4分前

Thanks that is interesting. However, how on earth they will be able to finance a DCVAX Direct medical trial is beyond me. Hopefully, a large pharma will inject a boa load of cash in NWBO. Also if MHRA does not approve then the DCVax-Direct program would be worthless therefore apparently NWBO expect

exwannabe

exwannabe 4分前

Prep to restart Direct:
So they are paying Advent to develop a new version of Direct. Not even in the clinic yet. Maybe they are looking for something better than a 0.0% ORR that the original Direct showed.

Hi_Lo

More incompetence from Sharp.

Nothing new.

gitreal

gitreal 5分前

This fraudulent garbage about to hit the trips. Promoters got better plays to pump elsewhere.

123tom

Your charting is worth looking at,Steve.
You were right about the rally.But it's looking like 10 might be the peak at the moment. It would be a double from the 5 bottom. Seems noteworthy to me. Avxl tends to retrace to the lower targets, which might be around 7 dollars , in this pattern. Som

beartrap12

beartrap12 5分前

Q10: The companies are particularly focusing on trial designs in which the primary endpoint will be tumor response (shrinkage), with potential timeframes in months, rather than time-to-event survival outcomes, with timeframes in years. The Company anticipates potentially being ready to submit an IND

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約